Format

Send to

Choose Destination
Cancer Prev Res (Phila). 2020 Feb;13(2):129-136. doi: 10.1158/1940-6207.CAPR-19-0378. Epub 2019 Dec 23.

Evaluating Lung Cancer Screening Across Diverse Healthcare Systems: A Process Model from the Lung PROSPR Consortium.

Author information

1
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. katharine.rendle@pennmedicine.upenn.edu.
2
Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.
3
Henry Ford Health System and Henry Ford Cancer Institute, Detroit, Michigan.
4
Marshfield Clinic Research Institute, Marshfield, Wisconsin.
5
Center for Health Research, Hawaii Permanente Medical Group, Kaiser Permanente Hawaii, Oahu, Hawaii.
6
Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
7
Division of Cancer Control and Population Sciences, NCI, Bethesda, Maryland.
8
Dana-Farber Cancer Institute, Boston, Massachusetts.
9
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
10
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.
11
School of Public Health, University of Michigan, Ann Arbor, Michigan.
12
Fred Hutchinson Cancer Research Center, Seattle, Washington.
#
Contributed equally

Abstract

Numerous organizations, including the United States Preventive Services Task Force, recommend annual lung cancer screening (LCS) with low-dose CT for high risk adults who meet specific criteria. Despite recommendations and national coverage for screening eligible adults through the Centers for Medicare and Medicaid Services, LCS uptake in the United States remains low (<4%). In recognition of the need to improve and understand LCS across the population, as part of the larger Population-based Research to Optimize the Screening PRocess (PROSPR) consortium, the NCI (Bethesda, MD) funded the Lung PROSPR Research Consortium consisting of five diverse healthcare systems in Colorado, Hawaii, Michigan, Pennsylvania, and Wisconsin. Using various methods and data sources, the center aims to examine utilization and outcomes of LCS across diverse populations, and assess how variations in the implementation of LCS programs shape outcomes across the screening process. This commentary presents the PROSPR LCS process model, which outlines the interrelated steps needed to complete the screening process from risk assessment to treatment. In addition to guiding planned projects within the Lung PROSPR Research Consortium, this model provides insights on the complex steps needed to implement, evaluate, and improve LCS outcomes in community practice.

PMID:
31871221
PMCID:
PMC7010351
[Available on 2021-02-01]
DOI:
10.1158/1940-6207.CAPR-19-0378

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center